Is your service suitable for clinical trials?

Creative Biolabs focuses exclusively on preclinical development. We provide research-grade materials and data for PoC studies but do not manufacture GMP-grade vaccines for human clinical use.

One-Stop Antigen Vaccine Development Solution

Q: What is the advantage of a Polyepitope vaccine over a single peptide vaccine?

Polyepitope vaccines ('string-of-beads') can include multiple epitopes from different antigens or for different HLA alleles. This increases the population coverage and prevents the tumor from escaping immune detection.

Q: When should I choose Undefined Antigen vaccines?

Undefined antigens (e.g., tumor lysates) are ideal when specific tumor antigens are unknown or highly heterogeneous, as they cover the full spectrum of patient-specific neoantigens.

Antigen vaccines work by presenting tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs) to the immune system, stimulating the production of high-affinity antibodies and potent cytotoxic T lymphocytes (killer T cells) to eliminate cancer cells.

As a global leader in preclinical vaccine engineering, Creative Biolabs offers a comprehensive antigen vaccine development service that integrates epitope discovery, structural design, and immunogenicity validation. Whether you are targeting defined antigens like hTERT and p16^INK4a, or utilizing undefined whole-tumor lysates, our advanced platforms ensure the generation of highly immunogenic vaccine candidates tailored to your specific research needs.

Get a Quote

Challenges in Antigen Vaccine Design

Developing an effective antigen vaccine requires overcoming significant biological hurdles. Simple injection of an antigen often fails to elicit a therapeutic response due to:

▶ Weak Immunogenicity: Self-antigens or small peptides often fail to trigger a robust immune alarm, leading to tolerance rather than activation.
▶ MHC Restriction: Peptide vaccines must match the diverse HLA alleles of the patient population to be effective.
▶ Antigen Escape: Tumors can downregulate single antigens, making mono-valent vaccines susceptible to resistance.
▶ Rapid Degradation: Free peptides are often degraded by proteases before they can be presented by Dendritic Cells (DCs).

Consult Our Scientists

Our Strategies & Solutions

To address these challenges, Creative Biolabs employs a "Rational Design" approach. We do not just synthesize antigens; we engineer them for maximum potency.

Epitope Enhancement

We modify peptide sequences to increase affinity for MHC molecules and T-cell receptors (TCRs), transforming weak self-antigens into potent immunogens.

Polyepitope Engineering

Connecting multiple CTL epitopes ("String-of-Beads" design) to broaden HLA coverage and prevent antigen escape, utilizing optimized linkers for correct processing.

Undefined Antigen Formatting

For uncharacterized tumors, we utilize whole tumor lysates, apoptotic bodies, or exosomes to create a personalized vaccine containing the full spectrum of patient-specific neoantigens.

Targeted Delivery

Coupling antigens with DC-targeting antibodies, nanoparticles, or viral vectors (e.g., Vaccinia) to ensure precise delivery to antigen-presenting cells.

Featured Development Services

Explore our specialized platforms for both defined and undefined antigen vaccines:

Peptide or Protein Based Vaccines

The most successful approach for melanoma and other solid tumors. We focus on specific epitopes (including mutant molecules) to avoid autoimmunity, using epitope enhancement to increase MHC affinity.

Learn More →

Polyepitope Vaccine Technology

Construction of recombinant polypeptides linking consecutive CTL epitopes. This technology broadens HLA coverage and avoids the toxicity and poor immunogenicity often associated with full-length antigens.

Learn More →

Undefined Antigen Based Vaccines

For malignancies with poorly characterized antigens. We develop vaccines using whole tumor cells (autologous/allogeneic), lysates, or tumor-APC fusion cells to induce broad-spectrum immunity.

Learn More →

hTERT Based Cancer Vaccine

Targeting the catalytic subunit of telomerase (hTERT), which is overexpressed in most cancers. We design vaccines to break tolerance against this universal tumor antigen without affecting normal stem cells.

Learn More →

p16^INK4a Based Cancer Vaccine

Restoring the immune surveillance against p16^INK4a, a tumor suppressor protein inactivated in many cancers. Our strategy focuses on inducing CTLs that recognize p16-overexpressing tumor cells.

Learn More →

FSPs Based Cancer Vaccine

Targeting Frameshift Peptides (FSPs) derived from microsatellite instability (MSI). These neo-epitopes are highly immunogenic and ideal for colorectal, endometrial, and pancreatic cancer vaccines.

Learn More →

Disease-Specific Solutions

We provide tailored antigen strategies for various solid tumors. Our library includes validated antigens for:

Development Workflow

From antigen identification to preclinical proof-of-concept, our rigorous process ensures the selection of the most potent vaccine candidates.

Step 1: Antigen Prediction & Selection

Activity: Utilizing bioinformatic algorithms to predict potential epitopes from tumor sequencing data. We screen for MHC binding affinity, proteasomal cleavage, and TAP transport efficiency.

Deliverable: A ranked list of candidate antigens/peptides.

Step 2: Structural Design & Enhancement

Activity: Optimizing peptide sequences via amino acid substitution (epitope enhancement) to increase MHC affinity. Designing "string-of-beads" constructs with optimal linkers for polyepitope vaccines.

Deliverable: Designed antigen sequences and vector maps.

Step 3: Synthesis & Formulation

Activity: High-purity peptide synthesis, recombinant protein expression, or generation of tumor lysates. Conjugation with carriers (e.g., KLH) or encapsulation in delivery systems.

Deliverable: Validated vaccine bulk material.

Step 4: In Vitro Immunogenicity Assay

Activity: Evaluating the vaccine's ability to stimulate T cells using ELISpot (IFN-γ release), Intracellular Cytokine Staining (ICS), and T-cell proliferation assays.

Deliverable: In vitro potency data report.

Step 5: In Vivo Efficacy (Animal Models)

Activity: Vaccinating syngeneic mice followed by tumor challenge. Monitoring tumor growth inhibition and survival rates to assess protective immunity.

Deliverable: Final preclinical study report (Research Use Only).

Start Your Project

Technology Platforms

Our solutions are underpinned by advanced platforms designed for precision immunology:

Advanced computational tools for rational vaccine design.

Prediction of MHC-I and MHC-II binding epitopes.
Molecular dynamics simulation of Peptide-MHC-TCR complexes.
Analysis of antigen processing and presentation pathways.

High-throughput production of high-purity antigens.

Automated peptide synthesis (up to 100 amino acids).
Recombinant protein expression in Mammalian/E. coli systems.
Production of long synthetic peptides (LSPs).

Comprehensive monitoring of immune responses.

ELISpot & FluoroSpot for cytokine detection.
MHC Multimer/Tetramer staining for specific T-cell quantification.
Flow cytometry-based cytotoxicity assays.

Specialized models for cancer vaccine testing.

Syngeneic mouse tumor models (Melanoma, Colon carcinoma, etc.).
Humanized mice (PBMC or HSC reconstituted).
Tumor re-challenge studies for memory response assessment.

Immunoinformatics Platform

Peptide & Protein Synthesis

Immune Monitoring

In Vivo Tumor Models

Inquire About Our Technology

Why Choose Creative Biolabs

Preclinical Leadership

We focus exclusively on research-grade and preclinical development, ensuring rapid iteration without the regulatory burden of GMP.

Rational Design

We don't just guess; we design antigens with enhanced affinity and stability to maximize immunogenicity.

Versatile Strategies

From defined single epitopes to complex whole-cell lysates, we cover every angle of antigen vaccination.

Proven Track Record

Successful delivery of thousands of peptide and protein antigens for cancer research worldwide.

Request a Free Consultation

Mechanism of Action

Antigen vaccines function by delivering tumor-specific proteins to Antigen-Presenting Cells (APCs), particularly Dendritic Cells (DCs). These APCs process the antigen and present key epitopes on their surface MHC molecules to T cells.

Key Objectives in Design:

✓ Breaking Tolerance: Since many tumor antigens are "self" proteins, vaccines must be engineered (e.g., via epitope enhancement) to look "foreign" enough to trigger an attack.
✓ Broadening Response: Using polyepitopes allows the vaccine to work across patients with different HLA types and targets multiple tumor subclones simultaneously.

Frequently Asked Questions

Q: What is the advantage of a Polyepitope vaccine over a single peptide vaccine?

A: Polyepitope vaccines ("string-of-beads") can include multiple epitopes from different antigens or for different HLA alleles. This increases the population coverage (more patients can respond) and prevents the tumor from escaping immune detection by downregulating a single antigen.

Q: What is "Epitope Enhancement" and why is it necessary?

A: Many tumor antigens are weak immunogens because they are "self" proteins. Epitope enhancement involves substituting specific amino acids in the peptide sequence to increase its binding affinity to MHC molecules, thereby triggering a stronger T-cell response without changing the T-cell recognition specificity.

Q: When should I choose Undefined Antigen vaccines (e.g., Tumor Lysates)?

A: Undefined antigens are ideal when the specific tumor antigens are unknown or highly heterogeneous. Using whole tumor lysates or autologous tumor cells ensures that the vaccine contains the full spectrum of patient-specific neoantigens (TSAs), reducing the chance of tumor escape.

Q: Can you assist with antigen design if the target sequence is unknown?

A:Absolutely. Our bioinformatics team can perform epitope mapping and structural analysis to identify high-potential immunogens. We utilize computational biology to predict B-cell and T-cell epitopes to maximize the immunogenicity of the vaccine candidate.

Q: What deliverables can I expect from an immunogenicity study?

A: You will receive a comprehensive report containing experimental design, raw data, and analysis. Typical readouts include ELISpot counts (IFN-γ secreting cells), flow cytometry plots showing T-cell activation markers, and cytotoxicity percentages.

Ask Our Experts